Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Abdominal aortic aneurysm (AAA) plasma proteomics

ABSTRACT: An abdominal aortic aneurysm (AAA) is a pathological dilatation of the aortic wall and it is a life-threatening disease due to the risk of rupture. Currently, surgical intervention remains the only definitive treatment recommended for large or rapidly expanding aneurysms. No pharmacological therapy is currently available to prevent AAA progression, as no drug has been proven effective. Diabetes is a major risk factor for cardiovascular disease in general. However, many studies over the last decade show that type 2 diabetes patients have a lower incidence of AAA and a slower aneurysm growth rate, which has been correlated with metformin use. We performed a proteomics analysis on plasma samples from controls, non-diabetic (ND) and diabetic (D) AAA patients. To prepare samples, we applied a novel approach known as Mag-Net, which utilizes hyper-porous, strong anion-exchange magnetic micro particles to isolate membrane-bound (exosomes, micro vesicles, and apoptotic bodies) particles from plasma. We aimed to identify AAA-related differences in the plasma proteome, focusing on underlying biological pathways and processes.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

DISEASE(S): Aortic Aneurysm

SUBMITTER: Thang Pham

LAB HEAD: Connie Jimenez

PROVIDER: PXD068130 | Pride | 2026-05-21

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	Compressed_search_Folder.zip	Other
	Plasma_peptide_table.tsv	Tabular
	Plasma_protein_table.xlsx	Xlsx
	Plasma_sample_labeling.xlsx	Xlsx
	TIM_240819_OPL1041_CdAM_JNL_Plasma_DDA_library_CUMULATIVE_library.tsv	Tabular

Items per page:

1 - 5 of 102

Similar Datasets

MULTI-OMIC ANALYSIS AND PLATELET FUNCTION DISTINGUISH TREATMENT RESPONSES TO HYDROXYTYROSOL IN CARDIOVASCULAR RISK

Project description:Many polyphenols, such as hydroxytyrosol (HT), have been recognized for their antioxidant and cardiovascular (CV) health benefits. To address the efficacy of HT, the present study aimed to identify the relevant mechanisms, associated with high-CV risk. Plasma unbiased multi-omics data were compared among two subgroups -HT responders and non-responders patients- and in a mice model. Lipid metabolism and proteomic responses were heterogeneous within two distinct ̶ responder and non-responder ̶ subgroups, associated mainly with thrombotic and hemostatic signals. The correlations between classical CV biomarkers, proteins, and metabolites offer a more comprehensive representation of the glutathione and coagulation pathways affected by HT treatment.

2025-07-01 | PXD060820 | Pride

Ontology-guided clustering enables proteomic analysis of rare pediatric disorders

Project description:The study of rare pediatric disorders is fundamentally limited by small patient numbers, making it challenging to draw meaningful conclusions about their molecular basis. To address this, we developed a framework that integrates clinical ontologies with proteomic profiling, enabling the systematic analysis of rare conditions in aggregate rather than isolation. We demonstrated this approach by analyzing urine and plasma samples from 1,140 children and adolescents, encompassing 394 distinct disease conditions and healthy controls. Using advanced mass spectrometry workflows, we achieved deep proteome coverage with over 5,000 proteins quantified in urine and 900 in plasma. By embedding SNOMED CT clinical terminology in a network structure and connecting it to proteomic data, we could group rare conditions based on their clinical relationships, allowing statistical analysis even for diseases with as few as two patients. This approach revealed molecular signatures across developmental stages and disease clusters while accounting for age- and sex-specific variation. Our framework provides a generalizable solution for studying heterogeneous patient populations where traditional case-control studies are impractical, bridging the gap between clinical classification and molecular profiling of rare diseases.

2025-06-10 | PXD058960 | Pride

abdominal aortic aneurysm (AAA) proteomics

Project description:An abdominal aortic aneurysm (AAA) is a pathological dilatation of the aortic wall and it is a life-threatening disease due to the risk of rupture. Currently, surgical intervention remains the only definitive treatment recommended for large or rapidly expanding aneurysms. No pharmacological therapy is currently available to prevent AAA progression, as no drug has been proven effective. Diabetes is a major risk factor for cardiovascular disease in general. However, many studies over the last decade show that type 2 diabetes patients have a lower incidence of AAA and a slower aneurysm growth rate, which has been correlated with metformin use. We performed a proteomics analysis on resected aortic tissue from controls, non-diabetic (ND) and diabetic (D) AAA patients.

2025-09-29 | PXD067859 | Pride

Plasma proteomics moyamoya disease

Project description:Moyamoya disease is a rare cerebrovascular disorder characterized by progressive stenosis of large intracranial arteries and a secondary compensatory network of vulnerable collaterals. While the underlying molecular mechanisms remain unclear, both genetic and immune factors have been implicated, calling for a multiomics approach to study the complex pathogenesis of the disease. We performed whole exosome sequencing and plasma proteomics on a cohort of twelve patients with well-documented moyamoya angiopathy. In addition, we conducted an in-depth single cell spatial proteomics analysis on an occluded artery retrieved post-mortem from one idiopathic patient. Variants in the major susceptibility gene RNF213 were found in three patients, while five patients had other underlying genetic conditions, including trisomy 21 and pathogenic variants in ACTA2, SAMHD1 and NFIA. Plasma proteomics revealed cellular fibronectin as a potential biomarker for moyamoya disease, while artery spatial proteomics profiling showed extensive vascular smooth muscle cell infiltration in the intima associated with phenotypic switching. Moreover, infiltration of macrophages and antigen-presenting cells points to a role for inflammatory signals in disease progression. Together, our study supports a multiomics approach to unravel the complex pathogenesis of moyamoya disease, demonstrating the relevance of genetic and immune triggers in vascular remodeling and moyamoya disease development.

2025-10-20 | PXD063236 | Pride

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

Project description:Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete description of specific immune biomarkers. We present here a comprehensive multi-omic blood atlas for patients with varying COVID-19 severity in an integrated comparison with influenza and sepsis patients versus healthy volunteers. We identify immune signatures and correlates of host response. Hallmarks of disease severity involved cells, their inflammatory mediators and networks, including progenitor cells and specific myeloid and lymphocyte subsets, features of the immune repertoire, acute phase response, metabolism and coagulation. Persisting immune activation involving AP-1/p38MAPK was a specific feature of COVID-19. The plasma proteome enabled sub-phenotyping into patient clusters, predictive of severity and outcome. Systems based integrative analyses including tensor and matrix decomposition of all modalities revealed feature groupings linked with severity and specificity compared to influenza and sepsis. Our approach and blood atlas will support future drug development, clinical trial design and personalized medicine approaches for COVID-19.

2022-02-22 | PXD023175 | Pride

GRASPing experience-dependent protein expression signatures enriched for hippocampal engram cell synapses

Project description:Enhanced synaptic wiring onto sparsely distributed memory engram cells supports contextual memory storage and recall, with negative-valence memories exhibiting greater salience. Protein-level adaptations of input-specific synaptic connectivity onto hippocampal CA1 engram cells, however, remains largely unexplored. By combining spatiotemporally restricted synapse labelling, sorting, and mass spectrometry, we generated a discovery-oriented proteomic dataset from samples enriched for CA1 engram cell synapses receiving CA3 input 72 h after neutral context exploration or aversive contextual fear conditioning. Differential analysis relative to an unlabelled comparator identified protein expression signatures associated with synapse structure, efficacy, and strength in CA1 engram cell synapses. Aversive learning induced predominantly postsynaptic protein expression patterns, whereas neutral context skewed towards presynaptic changes. This differential engram cell synapse proteome was enriched for genes linked to cognitive genetic traits and related disorders. Together, these data provide a first hypothesis-generating resource for investigations into the molecular basis of contextual memory at the level of the synapse.

2026-03-24 | PXD054892 | Pride

Human brain prefrontal cortex proteomics identifies compromised energy metabolism and neuronal function in Schizophrenia

Project description:Understanding the pathophysiological substrates of schizophrenia is a major challenge for current neuropsychiatric research. As part of a set of multi-omics experiments, we performed an extensive case-control proteomics study on 192 post-mortem tissue sections from prefrontal cortex from 96 individuals, including 47 cases with schizophrenia and 49 healthy controls. Using two independently measured cortical datasets, we identified 387 proteins differentially expressed between schizophrenia cases and controls at a 5% FDR threshold. This significantly regulated set of proteins contains genes located in GWAS-identified schizophrenia loci and proteins identified by pQTL analysis. Gene ontology analysis using GOAT provided evidence for regulation of several major protein categories, emphasizing downregulation of mitochondrial oxidative respiration, ribosomes and the proteasome, upregulation of kinases and (small) GTPases. SynGO analysis supports the notion of synaptic dysfunction in schizophrenia, with major regulators of pre- and postsynaptic function compromised. Our findings highlight the complex molecular dysregulation in schizophrenia, with mitochondrial function downregulated versus signaling and trafficking upregulated, and synapse function disrupted; in combination with prior avenues of research, these finding support a role for energy deficits compromising highly ATP dependent neuronal function as a target for therapeutic interventions.

2026-03-09 | PXD058441 | Pride

SFRP1 upregulation causes hippocampal synaptic dysfunction and memory impairment

Project description:Impaired neuronal and synaptic function are hallmarks of early stages Alzheimer's disease (AD) and are linked to cognitive decline, preceding other neuropathological traits. We have previously shown that SFRP1, a glial-derived protein elevated in the brains of AD patients from preclinical stages, contributes to AD progression, suggesting that glial factors may be important for early pathogenesis. Here, we have analyzed the hippocampus of newly generated transgenic mice overexpressing SFRP1 in astrocytes. We show that SFRP1 accumulation causes early dendritic and synaptic structural defects in adult mice. These changes are followed by poor synaptic long-term potentiation and cognitive impairment, evident only when the animals age, thereby mimicking the structural-functional temporal distinction observed in AD patients. These phenotypic traits are associated with an array of proteomic changes, including increased content of structural synaptic proteins, such as neurexin, which localizes in close proximity to SFRP1 along the processes of cultured hippocampal neurons. We conclude that excessive SFRP1 prevents the turnover of structural synaptic molecules, thereby reducing synaptic plasticity —a mechanism that may mirror the synaptopathy observed in the brains of prodromal AD patients.

2026-01-19 | PXD060276 | Pride

Lanifibranor reduces inflammation and improves dyslipidemia in lysosomal acid lipase-deficient mice

Project description:Background & Aims Recent studies showed that patients suffering from lysosomal acid lipase-deficiency (LAL-D) benefit tremendously from enzyme replacement therapy (ERT), however, the outcomes on liver histology in treated patients were inconsistent. The promising results of the pan-PPAR agonist lanifibranor in alleviating liver inflammation in patients with nonalcoholic steatohepatitis prompted us to investigate the effects of lanifibranor on liver pathology in LAL knockout (Lal-/-) mice. Methods Lal-/- mice were daily gavaged with lanifibranor or vehicle for 21 days. The effects of the treatment were assessed by measuring body and organ weights, plasma lipids and lipoproteins, as well as hematological parameters, followed by liver proteomics and metabolomics. Results Lanifibranor treatment slightly altered organ weights without affecting the total body weight of Lal-/- mice. We observed major changes in the proteome, with multiple proteins related to lipid metabolism, peroxisomal, and mitochondrial activities being upregulated and inflammation-related proteins being downregulated in the livers of treated mice. Hepatic lipid levels and histology remained unaltered, whereas plasma triglyceride and total cholesterol levels were decreased and the lipoprotein profile of lanifibranor-treated Lal-/- mice improved. Conclusions Lanifibranor treatment positively affected liver inflammation and lipoprotein homeostasis in Lal-/- mice. These findings support further evaluation of lanifibranor in combination with ERT for phenotype improvement in Lal-/- mice and a possible exploration avenue for the treatment of LAL-D in humans.

2024-06-12 | PXD047957 | Pride

Proteomic validation of MEG-01-Derived Extracellular Vesicles as Biologically Representative Models for Megakaryocyte- and Platelet-Derived Extracellular Vesicles.

Project description:Platelets and their extracellular vesicles (EVs) have emerged as promising liquid biopsy biosources for cancer detection and monitoring. The megakaryoblastic MEG-01 cell line offers a controlled system for generating platelet-like particles (PLPs) and EVs through valproic acid induced differentiation. Here, we performed comprehensive characterization and proteomic validation of MEG-01-derived populations, native human platelets and their EVs using nanoparticle tracking analysis, transmission electron microscopy, imaging flow cytometry and quantitative proteomics. MEG-01 megakaryocytic differentiation is characterized by polylobulated nuclei, proplatelet formation and elevated CD41/CD42a expression. PLPs predominantly exhibit an activated-like phenotype (CD62P+, degranulated morphology), while microvesicles (100-500 nm) and exosomes (50-250 nm) displayed size distributions and phenotypic markers consistent with native platelet-derived EVs. Proteomics identified substantial core proteomes shared across fractions and fraction-specific patterns consistent with selective cargo partitioning during EV biogenesis. Functional enrichment revealed that MEG-01-derived vesicles retained hemostatic, cytoskeletal and immune pathways characteristic of physiological platelet EVs. Ingenuity Pathway Analysis demonstrated that PLPs maintained proliferative transcriptional programs (elevated MYC/RB1/TEAD1, reduced GATA1), while plasma exosomes showed minimal differential pathway activation relative to MEG-01 exosomes. These findings validate MEG-01-derived EVs as representative of megakaryocyte-lineage exosomes and activated platelet-like states; plasma exosomes converge proteomically with EXOs MEG-01, whereas platelet exosomes retain distinct activation-associated features.

2026-01-05 | PXD070221 | Pride